FAQs

How can the biomarkers of a cancer vaccine be identified?

Based on HARCS platform, Creative Biolabs provides various strategies for cancer biomarker discovery, including but not limited to genetic sequencing, mass spectrometry, immunohistochemistry, NMR, HPLC, protein arrays, and chip analysis.

Which technologies can aid my cancer vaccine development?

Creative Biolabs has established several cancer vaccine technology platforms, including hematopoietic stem cell transplantation platform, polyepitope vaccine technology, tumor-APC fusion technology, anti-Tregs technology, and microfluidic cell-squeezing technology for B cell-based vaccines. With these advanced technologies, we can provide customized vaccine solutions for our clients.

Which cancer cell surface antigens are suitable for vaccine development?

A: Creative Biolabs has extensive experience in developing vaccines for cancer cell surface antigens such as ganglioside, polysialic acid, PSMA, Lewisy and Globo H, MUC1, CA125, and KSA. Additionally, we can provide clients with customized target development.

How can vaccine adjuvants be optimized?

Optimization of vaccine adjuvants requires a comprehensive and integrated consideration of the vaccine details, mainly in terms of:

Ⅰ. Biological activity aspects including safety, immune pathway, antigen dose, reaction range, antibody response, cell-mediated immunity, quality of the immune response, and improvement of the immune system.

Ⅱ. Physicochemical properties including raw materials, manufacturing process, particle morphology, antigen compatibility, stability.

Which vaccine adjuvants can be found at creative biolabs?

Based on our rich adjuvant product library, we can provide aluminum salts, oil adjuvant, liposomes, saponin and PRRs agonist to satisfy customers' different demands.

How does an adjuvant work in a vaccine?

Adjuvants are substances added to vaccines to improve the immune response to antigens. The main ways adjuvants work include increasing the recruitment and activation of APCs, inducing the release of cytokines that activate T cells, targeting antigens to specific locations, and slow-release of the antigen.

What are the main issues addressed by the vaccine during the preclinical study phase?

There are five main issues that need to be addressed:

Ⅰ. Determine whether humans develop protective immunity against infection, which increases the chances of successful vaccination.

Ⅱ. Identify which proteins or carbohydrates in microorganisms can stimulate immune cells and whether there are different forms of these proteins or carbohydrates in microorganisms.

Ⅲ. Explore whether immunostimulatory components of microorganisms can be packaged in the form of vaccines and delivered to experimental systems to stimulate an immune response.

Ⅳ. Investigate whether the immune response can protect against subsequent microbial infection and, if so, how long this protection lasts.

Ⅴ. Determine how large quantities of vaccines can be prepared in a consistent and cost-effective manner. (Consider it may not be economically feasible to produce vaccines that are labor-intensive or can only be produced in small quantities.)

How can I optimize my vaccine delivery system?

The optimization of the vaccine delivery system is a complex step. Firstly, you need to choose a suitable carrier, which is the core of the vaccine delivery system. Then, optimize the delivery method, which is related to the immunogenicity and safety of the vaccine. Lastly, select the appropriate adjuvant according to your antigen.

What products does Creative Biolabs offer to expedite vaccine research?

Creative Biolabs offers a variety of ready-to-use products to assist vaccine research, including adjuvants, delivery systems, ELISA kits, serum-free cell culture media, neutralizing antibodies for multiple pathogens, and high-quality antigens.

How can I determine the most suitable pathogen antigen?

The pathogen antigen is a critical component of a vaccine. Creative Biolabs leverages its extensive database to provide in silico models for candidate screening and vaccine design, thus improving efficiency.

Which assays can aid my vaccine preclinical study?

Creative Biolabs offers support for every stage of vaccine preclinical study, from antigen display to in vivo and in vitro assessment assays. Our rich expertise in immunology and microbiology can facilitate vaccine discovery.

How can I evaluate the in vivo immunogenicity of my vaccine?

Various animal models can be used to assess vaccine immunogenicity in vivo. Creative Biolabs provides natural disease models and surrogate models to study disease pathogenesis, host-pathogen interactions, and protection mechanisms after vaccination, infections, or disease treatment.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.